Unfortunately, despite the remarkable progress in TSC research over the last decade, conventional molecular testing fails to identify a pathogenic TSC1 or TSC2 mutation in 10 - 25% of individuals with TSC. This evidence concerns the gene TSC2 and tuberous sclerosis.